Segment and Other Information (Tables)

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Summary of Total Revenues

The following table presents a summary of total revenues (in thousands):

	Three Months Ended March 31,
	2016		2015
Xyrem® (sodium oxybate) oral solution	$	249,537	$	212,690
Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi)	51,173		50,353
Defitelio® (defibrotide sodium)/defibrotide	17,897		17,363
Prialt® (ziconotide) intrathecal infusion	6,209		6,764
Psychiatry	7,002		9,093
Other	2,098		10,772
Product sales, net	333,916		307,035
Royalties and contract revenues	2,094		2,268
Total revenues	$	336,010	$	309,303

Summary of Total Revenues Attributed to Geographic Sources

The following table presents a summary of total revenues attributed to geographic sources (in thousands):

	Three Months Ended March 31,
	2016		2015
United States	$	305,879	$	269,247
Europe	25,020		32,635
All other	5,111		7,421
Total revenues	$	336,010	$	309,303

Summary of Revenues from Customers Representing More Than 10% of Total Revenues

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:

	Three Months Ended March 31,
	2016		2015
Express Scripts	74	%	69	%
McKesson	13	%	1	%
Accredo Health Group, Inc.	—	%	13	%

Total Long-Lived Assets by Location

The following table presents total long-lived assets, consisting of property and equipment, by location (in thousands):

	March 31, 2016		December 31, 2015
Ireland	$	64,070	$	62,795
United States	12,757		12,794
Italy	7,941		7,928
Other	2,020		2,055
Total long-lived assets	$	86,788	$	85,572